Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)

NCT01520922 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

99

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia (CLL)
Leukaemia, Lymphocytic, Chronic

Interventions

BIOLOGICAL: Ofatumumab
DRUG: Bendamustine

Sponsor

Novartis Pharmaceuticals